Interleukin-13 receptor subunit alpha-2 (IL13Rα2) (IL13Rα2)

Interleukin-13 receptor subunit alpha-2 (IL-13Rα2) is a high-affinity monomeric receptor for the cytokine IL-13, historically characterized as a decoy receptor due to its lack of canonical JAK/STAT signaling motifs (Wikipedia, 2024). However, recent research has identified it as a functional signaling component in various cancers, where it activates alternative pathways such as AP-1, Src, and PI3K/Akt to drive tumor progression, invasion, and metastasis (Guide to Pharmacology, 2017). It is classified as a cancer-testis antigen, meaning its expression is restricted to the testes in healthy adults but is significantly upregulated in several malignancies, most notably glioblastoma multiforme (GBM), pancreatic cancer, and colorectal cancer (GeneCards, 2024). This restricted expression profile makes IL-13Rα2 a highly attractive therapeutic target for immunotherapies, including chimeric antigen receptor (CAR) T-cells, immunotoxins, and monoclonal antibodies (Frontiers in Oncology, 2021). Drugs targeting this receptor often utilize the high affinity of IL-13 or specific antibodies to deliver cytotoxic payloads directly to tumor cells. Despite its potential, clinical challenges include intra-tumoral heterogeneity of expression and the risk of antigen escape, where tumor cells downregulate the receptor to evade treatment (NIH, 2015).

Other names

CD213A2IL13RA2CT19IL-13RIL13BPCancer/Testis Antigen 19Interleukin-13-binding protein

Therapeutic agents targeting IL-13Rα2 employ several mechanisms: 1) Targeted cytotoxicity via immunotoxins (e.g., cintredekin besudotox) which are internalized upon binding to the receptor, leading to cell death (Frontiers in Oncology, 2021); 2) Chimeric Antigen Receptor (CAR) T-cell mediated lysis, where engineered T-cells recognize the antigen and destroy the tumor cell (NIH, 2015); 3) Antibody-drug conjugates (ADCs) that deliver cytotoxic payloads; and 4) DNA vaccines designed to elicit an immune response against cells expressing the antigen (GeneCards, 2024).